Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000258499 | SCV000328012 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000461006 | SCV000549814 | pathogenic | Hereditary breast ovarian cancer syndrome | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 22 of the BRCA2 gene. It does not directly change the encoded amino acid sequence of the BRCA2 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with breast cancer and/or hereditary breast and ovarian cancer (PMID: 21735045, 23479189, 24123850, 24607278, 24916970, 30702160). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 267712). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 21735045, 24123850, 24607278; Invitae). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV000562165 | SCV000665309 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2023-08-21 | criteria provided, single submitter | clinical testing | The c.8954-5A>G intronic variant results from an A to G substitution 5 nucleotides upstream from coding exon 22 in the BRCA2 gene. This alteration has been identified in several hereditary breast cancer families, and was found to segregate with disease in one family (Menéndez M et al. Breast Cancer Res. Treat., 2012 Apr;132:979-92; Santos C et al. J Mol Diagn, 2014 May;16:324-34; de Juan Jiménez I et al. Fam. Cancer, 2013 Dec;12:767-77). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. RT-PCR and minigene analyses determined that this alteration results in the creation of a novel splice acceptor site that causes an out of frame retention of 4 nucleotides of intron 21 (also called intron 22 in the literature) and results in a truncated mRNA transcript (Amrby internal data; Menéndez M et al. Breast Cancer Res. Treat., 2012 Apr;132:979-92; de Garibay GR et al. Hum. Mutat., 2014 Jan;35:53-7; Santos C et al. J Mol Diagn, 2014 May;16:324-34; Baert A et al. Hum. Mutat. 2018 Apr;39(4):515-526). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000461006 | SCV000695196 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2016-12-19 | criteria provided, single submitter | clinical testing | Variant summary: The BRCA2 c.8954-5A>G variant involves the alteration of a non-conserved intronic nucleotide. One in silico tool predicts a benign outcome for this variant. 5/5 splice prediction tools predict an alteration on normal splicing, which is confirmed by functional studies which shows the variant incudes aberrant splicing of intron 22 with the retention of its last 4 bp, which is predicted to result in out of frame product (de Garibay_2014, Menendez_2012, Santos_2014). This variant is absent in 120924 control chromosomes, but was reported in numerous affected individuals in the literature, including one family in which 1 carrier unaffected, two families with one non-carrier in each family had HBOC. These families show some level of non-segregation. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as likely pathogenic. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000985614 | SCV001133960 | likely pathogenic | not provided | 2018-10-16 | criteria provided, single submitter | clinical testing | Not found in the total gnomAD dataset, and the data is high quality (0/276278 chr). Found in at least one symptomatic patient. Predicted to negatively affect a known splice site. Nucleotide conservation is uninformative. Assessment of experimental evidence suggests this variant results in abnormal protein function. |
Color Diagnostics, |
RCV000562165 | SCV001339848 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-10-10 | criteria provided, single submitter | clinical testing | This variant causes an A to G nucleotide substitution at the -5 position of intron 22 of the BRCA2 gene. RNA studies found that this variant causes out-of-frame splicing of intron 22 (PMID: 21735045, 24123850, 24607278, 29280214), resulting in premature truncation. This variant has been reported in at least seven individuals affected with breast or ovarian cancer (PMID: 23479189, 24607278, 26187060, 35918668, DOI: 10.5603/OCP.2020.0026) and in families suspected of being affected with hereditary breast and ovarian cancer (PMID: 21735045, 24123850, 30415210, 33875706). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000985614 | SCV001447429 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000985614 | SCV001811038 | likely pathogenic | not provided | 2019-10-28 | criteria provided, single submitter | clinical testing | Non-canonical splice site variant demonstrated to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease (Menendez 2012, de Garibay 2014 Santos 2014, Baert 2017); Observed in individuals with personal and family history consistent with HBOC (de Juan Jimenez 2013, Santos 2014, Peixoto 2015); Not observed in large population cohorts (Lek 2016); Also known as 9182-5A>G; This variant is associated with the following publications: (PMID: 26187060, 24916970, 23479189, 31131967, 30702160, 30415210, 21735045, 24607278, 24123850, 29280214) |
Institute of Human Genetics, |
RCV003128237 | SCV003804733 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-01-27 | criteria provided, single submitter | clinical testing | _x000D_ Criteria applied: PS3_MOD, PS4_MOD, PM2_SUP, PP3 |
Research Molecular Genetics Laboratory, |
RCV000461006 | SCV000587982 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2015-12-17 | no assertion criteria provided | research | |
Department of Pathology and Laboratory Medicine, |
RCV000985614 | SCV000592239 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Center for Precision Medicine, |
RCV002250610 | SCV002520847 | likely pathogenic | Familial cancer of breast | no assertion criteria provided | literature only | ||
BRCAlab, |
RCV000258499 | SCV004243846 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2020-03-02 | no assertion criteria provided | clinical testing |